Kangji Medical Holdings Limited

DB:50J Stock Report

Market Cap: €949.1m

Kangji Medical Holdings Past Earnings Performance

Past criteria checks 3/6

Kangji Medical Holdings has been growing earnings at an average annual rate of 21.5%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 15.5% per year. Kangji Medical Holdings's return on equity is 21.1%, and it has net margins of 54.5%.

Key information

21.5%

Earnings growth rate

17.6%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate15.5%
Return on equity21.1%
Net Margin54.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Kangji Medical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:50J Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24981534181111
31 Mar 24953519176119
31 Dec 23926504171128
30 Sep 23892540158114
30 Jun 23858576146100
31 Mar 2382252813583
31 Dec 2278647912466
30 Sep 2274544712256
30 Jun 2270441512046
31 Mar 2269743611541
31 Dec 2169045710936
30 Sep 2165441310333
30 Jun 216173699629
31 Mar 215643109527
31 Dec 205112509525
30 Sep 205062278823
30 Jun 205002048121
31 Mar 205022057419
31 Dec 195032066717
31 Dec 183541474315
31 Dec 172481182910

Quality Earnings: 50J has high quality earnings.

Growing Profit Margin: 50J's current net profit margins (54.5%) are lower than last year (67.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 50J's earnings have grown significantly by 21.5% per year over the past 5 years.

Accelerating Growth: 50J's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 50J had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (10.1%).


Return on Equity

High ROE: 50J's Return on Equity (21.1%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kangji Medical Holdings Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Bo LiCLSA
Chris PanGoldman Sachs